The combination of optic neuritis and myelitis, the so-called Neuromyelitis optica is an uncommon pattern of demyelinating disorder. In 1870, Sir Thomas Clifford Allbutt first reported the association ...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...
Neuromyelitis optica spectrum disorders (NMOSD) are rare, relapsing inflammatory diseases of the central nervous system, predominantly affecting the optic nerves and spinal cord. Central to their ...
Joseph R. Berger, MD, shares significant insights regarding neuromyelitis optica spectrum disorders (NMOSD) presented at the recent ECTRIMS conference. Key findings focused on the disease's ...
Multiple sclerosis (MS) is a disease in which the body’s immune system attacks myelin, the outside layer of nerve cells. Neuromyelitis optica (NMO) is also an immune system attack. However, in this ...
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory disorder that typically affects the optic nerves and spinal cord. At least two thirds of cases are associated ...
TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that results from the phase III study of satralizumab (development code: SA237), SAkuraSky Study (NCT02028884), were ...
The early diagnosis and treatment of neuromyelitis optica (NMO) generally improve the outlook for people with this condition. Corticosteroids and immunotherapy are the main treatment options. NMO, ...
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Chugai's anti-interleukin-6 (IL-6) receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results